




























hreports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) 333–337
Available  online  at  www.sciencedirect.com
ScienceDirect
jou rn al hom ep age: ht tp : / /www.e lsev ier .com/ locate / rpor
eview
mproving  outcomes  in high-risk  prostate  cancer
ith radiotherapy
illiam R. Polkinghorn, Michael J. Zelefsky ∗
epartment of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY
0065, United States
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 30 August 2013
ccepted 15 October 2013
eywords:
igh-risk prostate cancer
xternal beam radiation therapy
ndrogen-deprivation therapy
nti-androgen agents
a  b  s  t  r  a  c  t
There have been signiﬁcant improvements in the radiotherapeutic management of patients
with high risk prostate cancer. Randomized trials have clearly demonstrated improved out-
comes with the combination of radiotherapy in conjunction with androgen deprivation.
While these trials have utilized low doses of radiotherapy in the range of 70 Gy, recent stud-
ies  have suggested that signiﬁcant beneﬁts of combined androgen deprivation therapy with
dose escalated radiotherapy are also observed. The use of high radiation dose levels in the
setting of high risk prostate cancer is important, and strategies which combine external
beam radiotherapy with a brachytherapy boost may provide an opportunity for even greater
intensiﬁcation of the radiation dose to the prostate target. Systemic therapies, second gen-ndrogen receptor eration anti-androgen therapy and novel targeted agents integrated with radiotherapy will
open up new vistas and challenges for further improved outcomes in patients with high-risk
disease.
©  2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
Clinical evidence suggests that not only is the use of.  Background
xternal beam radiation therapy (EBRT) is considered a
tandard treatment intervention for patients with high-risk
rostate cancer. However, EBRT alone is generally inade-
uate to achieve durable disease control for high-risk patients,
nd long-term outcomes with radiation therapy used as
onotherapy for this cohort are far from optimal. From the
adiotherapy-only arms of various randomized trials where
ow doses of EBRT in the ranges of 65–70 Gy were adminis-
ered, the 10-year prostate-speciﬁc antigen (PSA) failure rates
ere greater than 75%.1–4 Randomized trials1–4 for high-risk
rostate cancer have evaluated the combination of EBRT plus
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androgen-deprivation therapy (ADT) and have consistently
demonstrated improved outcomes with combined-modality
therapy for this high-risk population (Table 1). The greatest
beneﬁt may be seen among those patients with high-grade
cancers. This notion is further supported by a meta-analysis of
ﬁve Radiation Therapy Oncology Group (RTOG) trials incorpo-
rating 2743 patients5 where it was demonstrated that patients
with Gleason 8–10 or T3 disease experience superior survival
outcomes when treated with ADT in conjunction with EBRT
compared with EBRT alone.ADT in conjunction with EBRT an important element in the
management of high-risk prostate cancer, but in addition
the use of longer-durations of ADT may be associated with
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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Table 1 – Outcomes for combined androgen-deprivation therapy and radiotherapy in high-risk disease.
Study PSA failure Distant metastasis Prostate cancer death Overall survival
Pilepich et al.4 65% at 10 years 35% at 10 years 23% at 10 years 43% at 10 years
Horwitz et al.3 52% at 10 years 23% at 10 years 11% at 10 years 52% at 10 years
Pilepich et al.2 31% at 10 years (PSA < 1.5 ng/mL) 24% at 10 years 16% at 10 years 49% at 10 years
1 at 5 yBolla et al. 24% at 5 years 10% 
PSA = prostate-speciﬁc antigen.
improvement in survival outcomes. RTOG 92-02 included over
1500 patients and compared 28 months of ADT (consisting
of 2 months neo-adjuvant ADT, 2 months concurrent ADT
with EBRT, and 24 months adjuvant ADT) with 4 months
of ADT (consisting of 2 months neo-adjuvant ADT and 2
months concurrent ADT with EBRT without adjuvant ADT). In
a subset analysis, a 10% survival advantage was noted among
the Gleason 8–10 cohort who  received the long-term ADT reg-
imen compared with the short-course treatment.3 European
Organisation for Research and Treatment of Cancer (EORTC)
22961 randomized high-risk patients to 6 months ADT (neo-
adjuvant and concurrent ERBT) or 3 years of ADT (additional
30 months adjuvant ADT). Nine hundred seventy patients
were randomized to this trial, and with a median follow-up of
6.4 years a 4% survival advantage was observed for the group
treated with long-term ADT, with signiﬁcant improvement
in other parameters including progression-free survival
outcomes and biochemical relapse–free survival outcomes.1
Nevertheless, the optimal duration of ADT when adminis-
tered with radiation therapy (RT) remains to be deﬁned. In a
subset analysis of a Phase III trial from Canada that random-
ized high-risk patients to 3 versus 8 months of neo-adjuvant
ADT, patients were reported to have an improvement in 5-
year disease-free survival outcomes from 42% to 71% (P < 0.01);
however, no advantage was noted for overall survival.6 To
date, while it is common practice for patients with high-risk
disease to receive 2–3 years of adjuvant ADT, current trials
have never established if ADT courses with durations of only
12 or 18 months may be sufﬁcient, especially in the setting
of escalated doses of radiotherapy at 80 Gy or higher. Previ-
ously published trials comparing ADT plus EBRT versus EBRT
alone utilized low doses of radiotherapy, often in the absence
of targeted conformal treatment delivery such as intensity-
modulated radiotherapy. Therefore the optimal duration of
ADT remains unclear with the use of high-dose conformal
EBRT. Only randomized trials evaluating various ADT dura-
tions in the setting of high-dose radiotherapy administration
will be able to resolve these clinical uncertainties.
2.  Is  there  an  established  role  for  ADT  in
the  era  of  dose-escalated  IMRT  for  high-risk
patients?
Prior randomized trials1–4 in locally advanced prostate can-
cer demonstrating the beneﬁt of concomitant and adjuvant
ADT in conjunction with EBRT have all been in the set-
ting of low-dose radiotherapy. In retrospect, the dose levels
of 65–70 Gy (in the absence of conformal radiotherapy tech-
niques) routinely utilized in these studies would be considered
inadequate by current standards and associated with anears 6% at 5 years 78% at 5 years
increased likelihood of local tumor failure. Zelefsky et al.
have recently shown that even in the setting of dose levels of
81 Gy and higher, the use of ADT for higher-risk patients pro-
vides an incremental beneﬁt for improved PSA relapse-free
survival outcomes and distant metastases-free survival out-
comes. Zelefsky et al. reviewed the outcome of 2551 patients
treated with three-dimensional conformal radiotherapy (3D-
CRT)/IMRT with dose levels ranging from 64.8 Gy to 86.4 Gy.7 In
this experience the median duration of ADT was 6–8 months.
The use of ADT for intermediate- and high-risk patients was
associated with signiﬁcantly improved biochemical tumor
control and distant metastases-free survival outcomes. The
beneﬁt of ADT was observed even among patients who  were
treated to dose levels of 81 Gy or higher. These data suggest
that ADT (at least 6–8 months and probably longer) is still
required in conjunction with high-dose radiotherapy for high-
risk patients. We concur and believe that for high-risk prostate
cancer patients, longer courses of ADT such as 2–3 years would
be more  appropriate in the setting of high-dose radiotherapy
and represent our current practice.
3.  Dose  intensiﬁcation  with  EBRT  and
brachytherapy
Another important direction to improve the prostate cancer-
speciﬁc outcomes of high-risk patients includes the intensiﬁ-
cation of the radiation dose with the addition of brachytherapy
to external RT and ADT. It would appear that the use of tradi-
tional escalated radiation dose levels in the range of 78–80 Gy
may still be inadequate to eradicate locally advanced prostate
cancer. A meta-analysis of the Phase III dose-escalation tri-
als in patients for high-risk prostate cancer that comprised
over 2800 patients demonstrated continued improvements
in biochemical control outcomes with escalation of doses
from 64 Gy to 81 Gy, and there was no apparent suggestion
of a plateau being reached.8 Some reports have in fact noted
that dose-escalation even beyond 80 Gy has been associated
with similar improvements in tumor control outcomes.9,10
In one report from the Fox Chase Cancer Center investiga-
tors noted that patients who received doses of 80 Gy or more
had improved local and distant control compared with those
treated with doses less than 80 Gy.9 Pahlajani et al. noted that
for high-risk patients treated with EBRT there appears to be
an overall survival advantage with dose escalation up to 84 Gy
compared with doses <80 Gy.10
Several reports have noted improved outcomes with
combined-modality regimens of EBRT and brachytherapy. In
one study, 1342 patients with PSA >20 ng/mL, cT3 or higher,
or biopsy Gleason 8–10 prostate cancer were retrospectively
studied. Patients were treated with brachytherapy alone
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Fig. 1 – Natural history and therapeutic sequence of prostate cancer. Prostate cancer is classiﬁed by sensitivity to castration











































rommon upfront treatment is radiotherapy (RT) plus androg
r with supplemental ADT, RT or both; the analysis was
djusted for age, year of treatment, and other known prostate
ancer prognostic factors. After a median follow-up of 5.1
ears, there was a signiﬁcant reduction in the risk of prostate
ancer-speciﬁc mortality in men  treated with brachytherapy
nd both ADT and combined with external beam RT, further
ighlighting the need for greater dose intensiﬁcation in
igh-risk patients.11
Stock et al.12 reported the outcome of combined
rachytherapy with EBRT and ADT for high-risk prostate
ancer. These investigators reported on 181 prostate cancer
atients with Gleason scores 8–10 who were treated with a
d-103 implant (prescription dose 100 Gy), 45 Gy of EBRT, and
 months of ADT. The median follow-up was 5.5 years. The
-year PSA relapse-free survival and freedom from distant
etastases were 73% and 80%, respectively. The pretreatment
SA level signiﬁcantly affected freedom from biochemical
ailure, with 8-year rates of 72%, 82%, and 58% for patients
ith PSA level of ≤10, >10–20 and >20 ng/mL, respectively
P = 0.006). The PSA level had no signiﬁcant effect on rates
f distant metastases. The Gleason score had the most
igniﬁcant effect on freedom from biochemical failure in a
ultivariate analysis, and was the only factor to signiﬁcantly
ffect rates of distant metastases; the 8-year FBF rates were
4%, 55%, and 30% for scores of 8, 9, and 10, respectively
P = 0.003). The corresponding freedom from distant metas-
ases and prostate cancer-speciﬁc survival rates were 86%,
6%, 30% and 92%, 80%, 62.5%, respectively (P < 0.001).
.  Radiation  therapy:  adjuvant  treatment
ith  chemotherapy
n line with the adjuvant approach following radical prosta-
ectomy for high-risk prostate cancer, a feasibility trial to
ombine RT (70 Gy) and ADT (3 years) with adjuvant docetaxel
weekly 20 mg/m2 during RT followed by 3 cycles of 60 mg/m2
very 3 weeks) was performed.13 Of 50 patients enrolled, 46
atients completed a full-dose chemoradiation regimen. With
 median follow-up of 54 months, the 5-year clinical disease-
ree survival was 66.72% and the 5-year survival was 92.15%.
he authors concluded that 3D-CRT with androgen depriva-
ion and concurrent weekly docetaxel, followed by 3 cycles of
djuvant docetaxel may be considered as feasible in high-risk
rostate cancer and deserved to be evaluated in a Phase III
andomized trial.eprivation therapy (ADT).
5.  New  horizons
The overwhelming focus of present translational research has
been to develop effective treatments for castrate-resistant
prostate cancer, yet castrate-resistant prostate cancer for
many patients can be avoided altogether by improving upfront
radiotherapy for localized, high-risk disease (see Fig. 1). To
improve outcomes of deﬁnitive therapy for high-risk patients,
it is critical ﬁrst to determine the mechanism by which ADT
potentiates prostate cancer radioresponse. This has never
been more  clinically relevant given the recently demonstrated
success of second-generation anti-androgens in the treatment
of castration-resistant patients.14,15
Mechanisms proposed to explain how ADT potentiates
prostate cancer radioresponse include an increase in cell
death when ADT is combined with irradiation, decreased
tumor cell hypoxia,16 decreased DNA repair,17 and decreased
AR-mediated cell growth without evidence of direct synergy.18
Our group has recently demonstrated that the androgen recep-
tor (AR) in fact regulates a transcriptional program of DNA
repair genes in a direct manner, providing perhaps the most
compelling mechanism by which ADT improves the outcome
of radiotherapy (RT). Using a xenograft model of CRPC, we
demonstrated that second-generation anti-androgen therapy
downregulates DNA repair genes, and then by deploying RNA-
seq and ChIP-seq technologies deﬁned which of these genes
represent bona ﬁde AR target genes. We  next established
that these AR-mediated transcriptional changes are associ-
ated with decreased DNA repair when prostate cancer cells
are treated with irradiation plus ADT, and conversely with
increased DNA repair when cells are irradiated in the pres-
ence of androgen. However, perhaps most surprisingly, we also
demonstrated that primary prostate cancer tumors display a
signiﬁcant spectrum of AR transcriptional output and that this
variation directly correlates with the expression of a set of
DNA repair genes (unpublished data).
The observation that a wide spectrum of AR signaling
in primary tumors that correlates with DNA repair gene
expression has potentially signiﬁcant clinical implications.
The heterogeneity of AR output observed in patient samples
raises the tantalizing possibility that this may underlie het-
erogeneity in response from patients who  receive ADT and
radiotherapy. Speciﬁcally, inhibiting AR signaling in those
patients with high AR transcriptional output may result in
more  clinical beneﬁt than inhibiting AR signaling in those
patients with low AR transcriptional output. In this manner,
d rad
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prostate cancer may share more  in common with the other
classic hormonally-driven tumor, breast cancer. Just as
breast cancer patients are not indiscriminately treated with
tamoxifen but rather selected for hormonal therapy based
upon ER/PR positivity, it may be possible now to personalize
adjuvant hormonal therapy for prostate cancer patients. To
test this hypothesis, archived samples from landmark clinical
trials must be transcriptionally proﬁled and AR output must
be associated with clinical outcome. In collaboration with the
RTOG we  are actively engaged in this endeavor.
Once we  can identify those patients whose tumors depend
upon AR signaling, it is imperative that we take advantage of
new, more  potent anti-androgens by integrating these agents
as part of deﬁnitive radiotherapy. These anti-androgens,
such as abiraterone acetate and enzalutamide, have trans-
formed the treatment of castration-resistant disease by more
completely inhibiting both the production of endogenous
androgens (abiraterone) and more  effectively inhibiting the
androgen receptor (enzalutamide). The rationale for integrat-
ing these drugs as part of deﬁnitive radiotherapy for high-risk
prostate cancer is that, if moderate androgen deprivation in
the form of bicalutamide and leuprolide have clinical ben-
eﬁt, then more  potent androgen deprivation in the form of
a second-generation anti-androgen like enzalutamide and
leuprolide would be predicted to have even more  clinical ben-
eﬁt. In contrast to bicalutamide, which is a partial AR agonist,
enzalutamide is a far more  potent AR antagonist, as demon-
strated by comparing the expression of AR target genes, AR
ChiP, and AR nuclear localization between the two drugs.19
The next question is how to design adjuvant therapy for
those patients whose tumors exhibit low AR output and there-
fore appear to not depend as much upon AR signaling. The
challenge of how to create adjuvant therapy for the low AR
output patient can be approached using one of two broad
strategies: ﬁrst, manipulating the prostate cancer cell’s biology
to create (or perhaps recreate) AR dependence; and second, to
inhibit targets that may radiosensitize prostate cancer cells
independent of AR biology altogether. With respect to the ﬁrst
strategy, recent work has demonstrated that there exists an
inverse relationship between AR signaling and PI3K signaling
in which inhibition of one pathway activates the other and visa
versa.20 Speciﬁcally, Carver et al. demonstrated that in those
tumors in which PTEN is deleted, AR transcriptional output
is decreased and that PI3K inhibition activates AR signaling.
On the other hand, AR inhibition was found to activate AKT
signaling. Deploying combined pharmacologic inhibition of
AR and PI3K in a PTEN-deﬁcient transgenic mouse model
of prostate cancer resulted in near-complete regression. In
light of these data, it may be possible to create AR depen-
dence/sensitivity by treating patients with a PTEN-deleted
tumor with a drug that inhibits PI3K signaling along with an
antiandrogen. Therefore, for the patient with a PTEN-deleted
tumor who  is high risk and requires radiosensitization, a
compelling treatment regimen to test would be a second-
generation antiandrogen plus a PI3K signaling inhibitor (either
PI3K, AKT, or mTOR  inhibitor) delivered along with RT.The second strategy to treat patients whose tumors exhibit
low AR output would be to target aberrant pathways indepen-
dent of AR signaling. One target that has garnered signiﬁcant
interest recently is PARP1, which recent work has found toiotherapy 1 8 ( 2 0 1 3 ) 333–337
play a role in mediating the effects of the predominant ETS
gene fusion, TMPRSS2:ERG.21 Brenner et al. demonstrated that
TMPRSS2:ERG interacts in a DNA-dependent manner with
both PARP1 and DNA-PKcs, both of which are required for ETS-
mediated transcription and cell invasion. Therefore, in the
large number of patients with an ETS gene fusion, a reasonable
therapeutic strategy to test would be to combine radiotherapy
with PARP inhibition. Additional recent evidence has shown
that there may be some connection between PARP1 and AR
signaling. Schiewer et al. demonstrated that PARP-1 is an
important cofactor for AR activity, whereby PARP-1 activity is
required for AR function.22 Our own recent data demonstrate
that PARP-1 is a direct AR target gene whose expression is in
part regulated by AR activity (unpublished data). Given that
PARP1 levels are only partially decreased after AR inhibition,
in conjunction with the evidence that AR may promote DNA
repair through the increased expression of a number of differ-
ent DNA genes, we hypothesize that combined blockade of AR
and PARP-1 may maximally radiosensitize the cell compared
to either AR or PARP-1 inhibition alone.
6.  Conclusions
High-risk prostate cancer treated with radiotherapy is associ-
ated with improved outcomes when high-dose radiotherapy
is used in conjunction with ADT. It would appear that
the dose intensiﬁcation with ultra-high radiation doses can
be achieved most effectively when combining EBRT with a
brachytherapy boost. This approach can facilitate the deliv-
ery of greater radiobiologic dose levels than that of high-dose
radiotherapy delivered with IMRT  alone. Longer courses of
ADT appear to be associated with improved outcomes in
the high-risk prostate cancer population compared with
shorter courses. Future directions using second-generation
anti-androgen agents more  targeted to the androgen recep-
tor hold great promise for novel radiotherapeutic strategies
for high-risk prostate cancer.
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